Evidence map›Paper›PMID 40892309›Full record

ReviewActa ophthalmologica2026

Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care.

Davide Romano, Vito Romano, Alejandra Daruich, Giulio Ferrari, Matthieu Robert, Francesco Semeraro, Neil Lagali, Dominique Bremond-Gignac, ANIRIDIA‐NET Clinical Guidelines Working Group, Aniridia‐Europa and Geniris Working Group

Abstract readReview
In one paragraph

Review in Acta ophthalmologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Davide RomanoSt. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool, UK.ORCID https://orcid.org/0000-0002-8961-242X
Vito RomanoEye Clinic, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.ORCID https://orcid.org/0000-0002-5148-7643
Alejandra DaruichOphthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, Paris, France.ORCID https://orcid.org/0000-0001-7907-4325
Giulio FerrariDivision of Neuroscience, Cornea and Ocular Surface Disease Unit, Eye Repair Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0001-6474-9908
Matthieu RobertOphthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, Paris, France.
Francesco SemeraroOphthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, Paris, France.
Neil LagaliDepartment of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.ORCID https://orcid.org/0000-0003-1079-4361
Dominique Bremond-GignacOphthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, Paris, France.
ANIRIDIA‐NET Clinical Guidelines Working Group
Aniridia‐Europa and Geniris Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital aniridia is a rare ocular disorder affecting the majority of eye structures and can be associated with systemic manifestations. The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign. Other ocular comorbidities are associated with the disease, such as cataract, keratopathy and optic nerve hypoplasia. Mutation in the PAX6 gene is the most common cause of congenital aniridia, but other causative mutations exist. The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus. Management and follow-up of patients with congenital aniridia can be challenging due to the lack of effective therapeutic options and the complexity of ocular manifestations and outcomes. These guidelines for the diagnosis, management and care of congenital aniridia have been developed at the European level, thanks to ANIRIDIA-NET, based on a review of the scientific literature on clinical and molecular characterization, therapeutic options as well as non-medical approaches.

Indexed as

AniridiaDisease ManagementPractice Guidelines as TopicEuropeHumansMutationPAX6 Transcription FactorVisual AcuityPAX6 protein, humanPAX6 Transcription Factoraniridiaaniridia glaucomaaniridia guidelinesaniridia managementaniridia outcomeaniridia surgeryPAX6 gene

Identifiers

PMID40892309
PMCPMC13058686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.